These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation. Paine A; Oelke M; Tischer S; Heuft HG; Blasczyk R; Eiz-Vesper B J Immunother; 2010 Jan; 33(1):60-72. PubMed ID: 19952955 [TBL] [Abstract][Full Text] [Related]
5. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982 [TBL] [Abstract][Full Text] [Related]
6. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. Fleming T; Dunne J; Crowley B J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937 [TBL] [Abstract][Full Text] [Related]
7. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493 [TBL] [Abstract][Full Text] [Related]
8. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650 [TBL] [Abstract][Full Text] [Related]
9. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Ganepola S; Gentilini C; Hilbers U; Lange T; Rieger K; Hofmann J; Maier M; Liebert UG; Niederwieser D; Engelmann E; Heilbronn R; Thiel E; Uharek L Bone Marrow Transplant; 2007 Mar; 39(5):293-9. PubMed ID: 17262060 [TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. Kern F; Bunde T; Faulhaber N; Kiecker F; Khatamzas E; Rudawski IM; Pruss A; Gratama JW; Volkmer-Engert R; Ewert R; Reinke P; Volk HD; Picker LJ J Infect Dis; 2002 Jun; 185(12):1709-16. PubMed ID: 12085315 [TBL] [Abstract][Full Text] [Related]
11. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells. Van den Bosch GA; Van Gulck E; Ponsaerts P; Nijs G; Lenjou M; Apers L; Kint I; Heyndrickx L; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF J Immunother; 2006; 29(5):512-23. PubMed ID: 16971807 [TBL] [Abstract][Full Text] [Related]
13. Identification of T cell epitopes by the use of rapidly generated mRNA fragments. Britten CM; Meyer RG; Graf C; Huber C; Wölfel T J Immunol Methods; 2005 Apr; 299(1-2):165-75. PubMed ID: 15914199 [TBL] [Abstract][Full Text] [Related]
14. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Lacey SF; Diamond DJ; Zaia JA Biol Blood Marrow Transplant; 2004 Jul; 10(7):433-47. PubMed ID: 15205665 [TBL] [Abstract][Full Text] [Related]
15. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation. Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633 [TBL] [Abstract][Full Text] [Related]
16. Human bone marrow as a source to generate CMV-specific CD4+ T cells with multifunctional capacity. Na IK; Letsch A; Guerreiro M; Bauer S; Noack I; Geginat J; Reinke P; Loesch M; Kienapfel H; Thiel E; Volk HD; Scheibenbogen C J Immunother; 2009; 32(9):907-13. PubMed ID: 19816191 [TBL] [Abstract][Full Text] [Related]
18. Rapid generation of CMV pp65-specific T cells for immunotherapy. Bao L; Sun Q; Lucas KG J Immunother; 2007; 30(5):557-61. PubMed ID: 17589296 [TBL] [Abstract][Full Text] [Related]
19. Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses. Heine A; Grünebach F; Holderried T; Appel S; Weck MM; Dörfel D; Sinzger C; Brossart P Mol Ther; 2006 Feb; 13(2):280-8. PubMed ID: 16219490 [TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus (CMV) IE1- and pp65-specific CD8+ T cell responses broaden over time after primary CMV infection in infants. Gibson L; Dooley S; Trzmielina S; Somasundaran M; Fisher D; Revello MG; Luzuriaga K J Infect Dis; 2007 Jun; 195(12):1789-98. PubMed ID: 17492595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]